
Cocrystal Pharma COCP
$ 1.04
0.97%
Quarterly report 2025-Q3
added 11-14-2025
Cocrystal Pharma Interest Expense 2011-2026 | COCP
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Cocrystal Pharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 2 K | 4 K | 8 K | 19 K | 58 K | -7 K | 1.55 M | -11.4 M | 5.65 M | -3.34 M | -5.23 M | -1.24 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.65 M | -11.4 M | -1.16 M |
Quarterly Interest Expense Cocrystal Pharma
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | -220 K | - | -320 K | -140 K | - | - | 1 K | 1 K | 1 K | - | 1 K | 2 K | 1 K | - | 2 K | 2 K | 2 K | - | 5 K | 5 K | 4 K | - | 55 K | 55 K | 32 K | -152 K | 150 K | 198 K | 573 K | -762 K | 13 K | 977 K | 1.32 M | -1.38 M | 3.08 M | 1.25 M | 14.4 M | - | 50 K | - | - | - | -992 K | -482 K | -475 K | - | -483 K | -1.01 M | -3.47 M | - | -283 K | -109 K | -110 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.4 M | -3.47 M | 294 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Veracyte
VCYT
|
10.4 M | $ 31.01 | -5.46 % | $ 2.44 B | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Vir Biotechnology
VIR
|
-409 K | $ 8.47 | -5.47 % | $ 1.17 B | ||
|
Arena Pharmaceuticals
ARNA
|
4.16 M | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
Viking Therapeutics
VKTX
|
33.7 M | $ 32.67 | -4.61 % | $ 3.68 B | ||
|
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
16.4 M | - | - | $ 546 M | ||
|
Viridian Therapeutics
VRDN
|
95 K | $ 27.39 | -2.87 % | $ 2.79 B | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
-7.7 M | $ 437.99 | -3.47 % | $ 112 B | ||
|
Avid Bioservices
CDMO
|
4.34 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Verastem
VSTM
|
1.14 M | $ 5.01 | -5.29 % | $ 347 M | ||
|
VistaGen Therapeutics
VTGN
|
5 K | $ 0.56 | -7.23 % | $ 17.3 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
11.8 M | $ 12.88 | -7.74 % | $ 1.95 B | ||
|
vTv Therapeutics
VTVT
|
15 K | $ 38.69 | 2.35 % | $ 152 M | ||
|
Voyager Therapeutics
VYGR
|
1.65 M | $ 3.97 | -4.0 % | $ 233 M | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
5.2 M | $ 320.49 | -2.34 % | $ 42 B | ||
|
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
3.59 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
2.7 M | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
874 K | $ 1.07 | -1.82 % | $ 21.9 M | ||
|
Enochian Biosciences
ENOB
|
122 K | - | - | $ 40.5 M | ||
|
Equillium
EQ
|
-76 K | $ 1.93 | -6.31 % | $ 111 M |